Clinical use of approved influenza antivirals: Therapy and prophylaxis

Michael G. Ison*

*Corresponding author for this work

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Currently, there are two commonly used classes of antiviral agents approved for the prevention of and treatment for influenza: the M2 Inhibitors (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir, laninamivir, peramivir and zanamivir). These agents have been proven to be safe and effective alone or in combination for the treatment of uncomplicated influenza in otherwise healthy individuals. Although there are few prospective, randomized studies of these antivirals for the treatment of pregnant women, hospitalized patients, and immunocompromised patients infected with seasonal, pandemic, or avian H5N1 influenza, these agents are widely used for these indications. This article reviews the pharmacokinetics and clinical data available relative to the use of commercially available antiviral agents for the prevention of and treatment for influenza.

Original languageEnglish (US)
Pages (from-to)7-13
Number of pages7
JournalInfluenza and other respiratory viruses
Volume7
Issue number1 SUPPL.1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Human Influenza
Antiviral Agents
R 125489
Rimantadine
Zanamivir
Oseltamivir
Amantadine
Influenza in Birds
Immunocompromised Host
Neuraminidase
Pandemics
Therapeutics
Pregnant Women
Pharmacokinetics
Prospective Studies

Keywords

  • Adamantanes
  • Antiviral agents
  • Influenza
  • M2 inhibitors
  • Neuraminidase inhibitors

ASJC Scopus subject areas

  • Infectious Diseases
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

@article{48bda01fc8494d3b9efa1990d5ae4240,
title = "Clinical use of approved influenza antivirals: Therapy and prophylaxis",
abstract = "Currently, there are two commonly used classes of antiviral agents approved for the prevention of and treatment for influenza: the M2 Inhibitors (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir, laninamivir, peramivir and zanamivir). These agents have been proven to be safe and effective alone or in combination for the treatment of uncomplicated influenza in otherwise healthy individuals. Although there are few prospective, randomized studies of these antivirals for the treatment of pregnant women, hospitalized patients, and immunocompromised patients infected with seasonal, pandemic, or avian H5N1 influenza, these agents are widely used for these indications. This article reviews the pharmacokinetics and clinical data available relative to the use of commercially available antiviral agents for the prevention of and treatment for influenza.",
keywords = "Adamantanes, Antiviral agents, Influenza, M2 inhibitors, Neuraminidase inhibitors",
author = "Ison, {Michael G.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1111/irv.12046",
language = "English (US)",
volume = "7",
pages = "7--13",
journal = "Influenza and other Respiratory Viruses",
issn = "1750-2640",
publisher = "Wiley-Blackwell",
number = "1 SUPPL.1",

}

Clinical use of approved influenza antivirals : Therapy and prophylaxis. / Ison, Michael G.

In: Influenza and other respiratory viruses, Vol. 7, No. 1 SUPPL.1, 01.01.2013, p. 7-13.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical use of approved influenza antivirals

T2 - Therapy and prophylaxis

AU - Ison, Michael G.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Currently, there are two commonly used classes of antiviral agents approved for the prevention of and treatment for influenza: the M2 Inhibitors (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir, laninamivir, peramivir and zanamivir). These agents have been proven to be safe and effective alone or in combination for the treatment of uncomplicated influenza in otherwise healthy individuals. Although there are few prospective, randomized studies of these antivirals for the treatment of pregnant women, hospitalized patients, and immunocompromised patients infected with seasonal, pandemic, or avian H5N1 influenza, these agents are widely used for these indications. This article reviews the pharmacokinetics and clinical data available relative to the use of commercially available antiviral agents for the prevention of and treatment for influenza.

AB - Currently, there are two commonly used classes of antiviral agents approved for the prevention of and treatment for influenza: the M2 Inhibitors (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir, laninamivir, peramivir and zanamivir). These agents have been proven to be safe and effective alone or in combination for the treatment of uncomplicated influenza in otherwise healthy individuals. Although there are few prospective, randomized studies of these antivirals for the treatment of pregnant women, hospitalized patients, and immunocompromised patients infected with seasonal, pandemic, or avian H5N1 influenza, these agents are widely used for these indications. This article reviews the pharmacokinetics and clinical data available relative to the use of commercially available antiviral agents for the prevention of and treatment for influenza.

KW - Adamantanes

KW - Antiviral agents

KW - Influenza

KW - M2 inhibitors

KW - Neuraminidase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84871824506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871824506&partnerID=8YFLogxK

U2 - 10.1111/irv.12046

DO - 10.1111/irv.12046

M3 - Article

C2 - 23279892

AN - SCOPUS:84871824506

VL - 7

SP - 7

EP - 13

JO - Influenza and other Respiratory Viruses

JF - Influenza and other Respiratory Viruses

SN - 1750-2640

IS - 1 SUPPL.1

ER -